

Carmen Baldazzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8998611/publications.pdf>

Version: 2024-02-01

79
papers

937
citations

686830

13
h-index

454577

30
g-index

79
all docs

79
docs citations

79
times ranked

1633
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1 ⁺ positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). <i>Blood</i> , 2009, 114, 2159-2167.	0.6	201
2	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012, 120, 761-767.	0.6	110
3	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2011, 117, 6793-6800.	0.6	98
4	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. <i>Leukemia</i> , 2018, 32, 1609-1620.	3.3	80
5	Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. <i>Stem Cell Research and Therapy</i> , 2018, 9, 271.	2.4	63
6	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. <i>Blood</i> , 2009, 114, 4939-4943.	0.6	62
7	Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. <i>Cancer</i> , 2019, 125, 712-725.	2.0	49
8	B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. <i>Leukemia Research</i> , 2010, 34, e282-e285.	0.4	37
9	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 99.	6.9	35
10	Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. <i>Cancer Genetics and Cytogenetics</i> , 2010, 199, 76-80.	1.0	28
11	Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. <i>Oncotarget</i> , 2017, 8, 29906-29913.	0.8	22
12	Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. <i>Oncotarget</i> , 2015, 6, 31284-31294.	0.8	18
13	Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1951.	1.7	17
14	Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. <i>Leukemia</i> , 2021, 35, 2813-2826.	3.3	15
15	Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis. <i>Blood</i> , 2013, 122, 2622-2622.	0.6	11
16	Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. <i>Leukemia Research</i> , 2009, 33, e218-e220.	0.4	9
17	Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. <i>Leukemia and Lymphoma</i> , 2009, 50, 114-118.	0.6	9
18	Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells. <i>Haematologica</i> , 2017, 102, 1204-1214.	1.7	8

#	ARTICLE	IF	CITATIONS
19	Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). <i>Blood</i> , 2011, 118, 2756-2756.	0.6	7
20	4q12 translocations with <i>GSX2</i> expression identify a <i>CD7⁺</i> acute myeloid leukaemia subset. <i>British Journal of Haematology</i> , 2015, 171, 141-145.	1.2	6
21	Complex chromosomal rearrangements leading to <i>MECOM</i> overexpression are recurrent in myeloid malignancies with various 3q abnormalities. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 375-388.	1.5	5
22	<i>FGFR1</i> and <i>KAT6A</i> rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features. <i>American Journal of Hematology</i> , 2016, 91, E14-6.	2.0	4
23	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2020, 105, 47-55.	1.1	4
24	Acute promyelocytic leukemia with amplification of PML-RAR α rearrangement: Clinical implications. <i>Leukemia Research</i> , 2008, 32, 1941-1943.	0.4	3
25	Chromothripsis in acute myeloid leukemia: Biological features and impact on survival. <i>Leukemia</i> , 2017, , .	3.3	3
26	Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients. <i>Leukemia Research</i> , 2021, 101, 106497.	0.4	3
27	Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway. <i>Blood Cancer Journal</i> , 2021, 11, 7.	2.8	3
28	PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients. <i>Blood</i> , 2011, 118, 1429-1429.	0.6	3
29	Gas1 and Kif27 Genes Are Strongly up-Regulated Biomarkers of Hedgehog Inhibition (PF-04449913) on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients. <i>Blood</i> , 2011, 118, 1535-1535.	0.6	3
30	Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome. <i>Blood</i> , 2014, 124, 484-484.	0.6	3
31	Abstract 906:Gas1andKif27genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients. , 2012, , .		2
32	Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harboring FLT3 Mutations in AML Patients. <i>Blood</i> , 2014, 124, 1040-1040.	0.6	2
33	RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3627-3627.	0.6	2
34	Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7038-7038.	0.8	2
35	Mitoxantrone, Etoposide and Cytarabine (MEC) Can Induce Deep Complete Remission and Is an Effective Bridge Therapy to Allograft Transplantation (SCT) in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients. <i>Blood</i> , 2018, 132, 4036-4036.	0.6	2
36	A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia. <i>Hematology Reports</i> , 2012, 4, e27.	0.3	1

#	ARTICLE	IF	CITATIONS
37	Abstract 746: PKC412 (Midostaurin) is safe and highly effective in systemic mastocytosis patients: Follow up of a single-center Italian compassionate use. , 2014, , .		1
38	Deletions of the Derivative Chromosome 9 Do Not Influence Response to Imatinib of Early Chronic Phase Chronic Myeloid Leukemia Patients (A GIMEMA Working Party Analysis).. Blood, 2006, 108, 2112-2112.	0.6	1
39	Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50. Blood, 2016, 128, 1702-1702.	0.6	1
40	Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL).. Blood, 2009, 114, 167-167.	0.6	1
41	Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing. Blood, 2014, 124, 1028-1028.	0.6	1
42	Abstract 90: A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia. Cancer Research, 2016, 76, 90-90.	0.4	1
43	Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML). Blood, 2016, 128, 1679-1679.	0.6	1
44	Tyrosine Kinase Inhibitors (TKI) in Relapsed/Refractory (RR) Patients with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Confer Better Survival than Chemotherapy, Due to a Better Safety Profile. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S200.	0.2	0
45	Age, Disease Status before Blinatumomab, MRD Negativity Obtainment, and Bridge to Transplant Influence Outcome in Patients with B-ALL: A Single Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S181-S182.	0.2	0
46	C22orf2 Gene (22q13.1) Translocation Downstream of Bcr Breakpoint (22q11) to the Derivative 9 Chromosome Is Associated with Reduced Expression of Its Protein, the Beta-Catenin Antagonist Chibby, in Chronic Myeloid Leukemia Progenitors. Blood, 2011, 118, 1676-1676.	0.6	0
47	PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience. Blood, 2012, 120, 1749-1749.	0.6	0
48	Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q). Blood, 2013, 122, 5227-5227.	0.6	0
49	Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harboring T315I Mutation: The Bologna Experience. Blood, 2013, 122, 3911-3911.	0.6	0
50	PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis: Follow up of a single-center Italian compassionate use.. Journal of Clinical Oncology, 2014, 32, 7113-7113.	0.8	0
51	Abstract 570:Tp53mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome. , 2014, , .		0
52	Abstract CT312: Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience. , 2014, , .		0
53	SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients. Blood, 2014, 124, 1030-1030.	0.6	0
54	Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia. Blood, 2014, 124, 2352-2352.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Abstract B03: Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome.. , 2015, , .		0
56	Abstract 4906: TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome. , 2015, , .		0
57	Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients. Blood, 2015, 126, 3198-3198.	0.6	0
58	Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2015, 126, 2513-2513.	0.6	0
59	A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene. Blood, 2015, 126, 1356-1356.	0.6	0
60	A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium. Blood, 2015, 126, 3840-3840.	0.6	0
61	Upregulation of Indoleamine 2,3-Dioxygenase Enzymes in Leukemic Mesenchymal Stromal Cells (MSCs) Can Influence MSC/Acute Myeloid Leukemia Cell Cross Talk. Blood, 2015, 126, 1191-1191.	0.6	0
62	Pharmacological interaction and side effects in oncohaematology: a retrospective observational study.. Journal of Clinical Oncology, 2016, 34, e18235-e18235.	0.8	0
63	Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis.. Journal of Clinical Oncology, 2016, 34, 7044-7044.	0.8	0
64	Abstract 113: Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia. , 2016, , .		0
65	Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis. Blood, 2016, 128, 1677-1677.	0.6	0
66	Copy number variants signature in two patients with relapsed acute promyelocytic leukemia.. Journal of Clinical Oncology, 2017, 35, e23207-e23207.	0.8	0
67	Microarray analysis to identify novel copy number alterations in acute myeloid leukemia.. Journal of Clinical Oncology, 2017, 35, 11622-11622.	0.8	0
68	Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia.. Journal of Clinical Oncology, 2017, 35, 11611-11611.	0.8	0
69	Abstract 1766: Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients. , 2017, , .		0
70	Abstract 3472: Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels. , 2017, , .		0
71	Abstract 2951: Gene expression profiling identifies new adult "triple-negative" acute lymphoblastic leukemia (ALL) subgroups. , 2018, , .		0
72	Abstract 656: Distinct pattern of alterations in TP53 mutated/deleted and wild-type high risk acute myeloid leukemia (AML) patients: Identification of new "targetable" genes/pathways. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
73	A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups. Blood, 2018, 132, 5284-5284.	0.6	0
74	Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics. Blood, 2018, 132, 2748-2748.	0.6	0
75	Abstract 2140: "3c-up" a new adult Philadelphia negative acute lymphoblastic leukemia subgroup: Novel molecular markers. , 2019, , .		0
76	The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience. Blood, 2019, 134, 5098-5098.	0.6	0
77	AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA). Blood, 2019, 134, 2617-2617.	0.6	0
78	Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting. Blood, 2020, 136, 14-15.	0.6	0
79	Abstract 3100: Blinatumomab is safe and effective in relapsed and MRD positive B-ALL CD19+ patients: The bologna compassionate program experience. , 2019, , .		0